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BACKGROUND: Ovarian cancer is the most lethal gynaecological cancer. Progression-free and overall survival is significantly related to
surgical success and residual disease volume. It is unclear whether this survival advantage is due to an intrinsic biological element of the
tumour cells which enables successful surgery and improved prognosis, or alternatively the number of tumour sustaining cells
remaining irrespective of differences in biology.
METHODS: A systematic review of the literature was performed identifying studies that have investigated the association between
biomarkers and surgical outcomes. We attempted validation of these results using The Cancer Genome Atlas ovarian cancer
data sets.
RESULTS: Thirty studies were identified of which sixteen determined protein expression, eight gene expression and one DNA
methylation in association with surgical debulking. Individualised linear models adjusting for batch, stage and age identified only
expression of the genes MTDH and insulin-like growth factor-1 receptor (IGF1R) to be significantly associated with debulking surgery
(Po0.05, false discovery rate (FDR)o5%), although in the case of IGF1R this was in the opposite direction to previous findings.
CONCLUSION: The majority of studies are limited by design, include heterogeneous samples and lack adjustment for major confounding
factors. High quality detailed clinical annotations should be routinely collected in future to more accurately evaluate biomarkers of
surgical outcome.
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Ovarian cancer is the second commonest and most lethal of all
gynaecological cancers. In the United Kingdom, B6500 new cases
are diagnosed every year with the majority presenting with
advanced disease (Cancer Research UK, 2011). Over the past 30
years, despite advances in chemotherapeutic agents, there has been
little change to overall survival (OS) with current 5-year survival at
B35% (Coleman et al, 2011). The standard treatment for epithelial
ovarian carcinoma (EOC) is primary surgery, which usually
includes total abdominal hysterectomy, bilateral salpingoophrect-
omy, omentectomy and lymphadenectomy in some cases, followed
by adjuvant platinum-based chemotherapy with or without
paclitaxel. Surgical success is an important prognostic factor and
it is widely accepted that volume of residual disease after primary
surgery influences OS following treatment (Pomel et al, 2008; Shih
and Chi, 2010). This appears to be true independent of the type of
chemotherapy used (Vergote et al, 2010). The Gynaecologic
Oncology Group has classified cytoreductive surgery to describe
the amount of residual disease at the end of surgery (Hoskins et al,
1994). Optimal debulking currently refers to a maximal diameter of
residual tumour p1 cm, whereas suboptimal debulk describes
residual tumours 41 cm in diameter. Meta-analysis of published
data in post platinum era shows a positive correlation between
surgical debulk status and survival in advanced disease (Bristow
et al, 2002). For every 10% increase in maximal cytoreduction,
there appears to be a 5.5% increase in median survival. There is
now growing evidence that in fact total (or complete) macroscopic
debulking, defined by an absence of any macroscopic tumour post-
operatively, is one of the most important factors in survival
(Wimberger et al, 2007, 2010; Eisenhauer et al, 2008; Colombo
et al, 2009) with a reported increase in OS of 14–28 months in
patients with total debulking as compared with optimally debulked
patients. This appears to be true for all histological subtypes
including clear cell, a particularly aggressive form of EOC (Takano
et al, 2006). There are two arguments for this survival benefit; (1)
that with minimal residual disease there are less malignant cells
present and thus improved subsequent ability for chemotherapy to
reach the centre of the tumour and a decreased rate of
chemotherapy resistance, (2) an intrinsic biological element of
the tumour cells leads to a less aggressive, less invasive disease that
incurs a survival advantage and additionally allows a more
successful surgical outcome. The crucial question of whether there
is evidence for a role of tumour biology in determining surgical
outcome is still unanswered (Chi and Schwartz, 2008). In the
United Kingdom, all patients with suspected EOC undergo
preoperative assessment in a bid to plan and predict surgical
treatment. This includes assessment of tumour load through level
of tumour markers, ultrasound scans, computer tomography (CT)
and magnetic resonance imaging (MRI). However, despite this
ability to preoperatively assess the involvement of certain organs,
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true extent of disease is often difficult to ascertain. Much emphasis
has been placed on investigating the use of the tumour marker
cancer antigen 125 (Ca125) and imaging modalities as a possible
predictive model of surgical outcome but without success (Ibeanu
and Bristow, 2010). If tumour biology did determine surgical
success, then biomarkers could potentially be developed that
predicted outcomes of surgery and aided clinical treatment
decisions. In this systematic review, we aim to summarise the
evidence to date and attempt to validate previous findings through
the publically available The Cancer Genome Atlas (TCGA) gene
expression and DNA methylation data sets from patients with
high-grade and advanced stage serous EOC.
METHODS
Systematic literature search
A systematic literature search was performed in PUBMED using
the search terms ((debulking surgery) OR (optimal suboptimal)
OR (cytoreduct*)) AND (ovarian cancer) AND ((microarray) OR
(gene expression) OR (protein expression) OR (DNA methyla-
tion)). Inclusion criteria for the studies were as follows: primary
diagnosis of EOC, primary peritoneal or fallopian tube carcinoma,
tissue taken from patients undergoing primary surgery, optimal
and suboptimal debulking categories defined. Articles were
excluded if they were not written in English, if the study was not
performed on human tissue, if there were no specific results in
relation to surgical outcome, if surgical debulking was not defined
or if patients had neoadjuvant chemotherapy or interval debulking
surgery. From inclusive dates of January 1990 to September 2011,
the search initially yielded 144 articles in PUBMED. Inspection of
abstracts to exclude publications lacking relevant clinical informa-
tion narrowed the search to 41 potential studies. These articles
were read in full and the reference lists were searched manually,
yielding one further study. From a total of 42 studies, 2
publications were excluded as they were not written in English, 6
were excluded as they included tissue taken at recurrence or after
chemotherapy, 2 were excluded as there was failure to define
debulking surgery or residual disease, 1 was excluded as neither
debulking nor primary surgery was defined and 1 was excluded as
it was unclear whether tumours were epithelial ovarian in origin.
The final 30 publications that met inclusion criteria are described
in Supplementary Tables 1–3.
TCGA data set
Data consisting of 311 high-grade serous ovarian tumours were
obtained from the TCGA data portal (http://cancergenome.nih.
gov/dataportal). Level 2 expression data on Affymetrix HGU133A
microarrays and level 3 methylation data on Illumina Human
Methylation27 Beadchip and annotated clinical data were
obtained. Methods including sample inclusion criteria, sample
processing and quality control are previously published (Cancer
Genome Atlas Research Network, 2011; Dai et al, 2011). Our
analysis of these data was limited to the 279 patients with stage 3 or
4 serous EOC that contained details describing volume of residual
disease. We performed power calculations to ensure the TCGA
validation set was adequately powered to detect effects seen in
previously published studies for markers we found to be
significant (insulin-like growth factor-1 receptor (IGF1R) – An
et al, 2009 and AEG1 – Li et al, 2011) and those we did not
(HOXA11 – Fiegl et al, 2008). Individual generalised linear models
were used to determine the association between gene expression
and DNA methylation of specific loci with surgical debulking
status adjusting for microarray batch, age at diagnosis and stage.
Multiple comparisons were accounted for in the models using false
discovery rate (FDR) estimation to calculate q values. Statistical
analyses were performed using the R statistical package (version
2.10 at http://www.r-project.org) and power calculations were
performed following previously published methods (Demidenko,
2007).
RESULTS
Protein expression associated with surgical outcomes
Sixteen out of the thirteen publications included data on protein
expression in relation to clinical characteristics and surgical
debulking outcomes. Supplementary Table 1 describes the main
characteristics of each study; all used immunohistochemistry to
determine levels of protein expression. Eleven of the studies were
single studies investigating different proteins. Increased expression
of Cyclin E (Rosen et al, 2006), c-erbB-2 (Simpson et al, 1995),
Twist protein (Hosono et al, 2007), p63a (Jewell et al, 2009),
ERCC1 (Lin et al, 2010), AEG-1 (Li et al, 2011) and P130cas (Nick
et al, 2011) have all been shown to be associated with suboptimal
debulking. The majority of studies included all types of EOC
histology and all stages of disease in analysis although this could
lead to confounding and bias. For example, in one study increased
expression of COX-2 protein was significantly related to sub-
optimal debulking surgery (defined as residual disease 42 cm) in
64 EOC samples (P¼ 0.027) (Seo et al, 2004). However in subset
analysis, using only serous and endometroid tumours (n¼ 46)
there was no longer a significant association with debulking
surgery (P¼ 0.743). Additionally, it should be noted that all the
studies identified used univariate statistical analysis to find
associations between protein expression and surgery. As surgical
debulking is strongly associated with stage these results may
indicate an association with stage rather than surgical outcome.
Four publications were identified that explored the relationship
of p53 and residual disease, of which two found a significant
association with p53 protein overexpression and suboptimal
debulking in univariate analysis (n¼ 82, P¼ 0.01) (Dogan et al,
2005) (n¼ 83, Po0.041) (Geisler et al, 1997), one demonstrated a
trend to overexpression and suboptimal debulking (n¼ 136,
P¼ 0.07) (Ferrandina et al, 1999) and one did not find a significant
association (n¼ 79, P¼ 0.36) (Bar et al, 2001). These four studies
used heterogeneous histological samples, variable clinical stages
and varying definitions of suboptimal and optimal debulking.
Results from a meta-analysis have highlighted the association
between p53 expression and stage in ovarian cancer (de Graeff
et al, 2009) and thus again there are likely to be important
confounding factors.
Gene expression associated with surgical outcomes
There were 8 studies out of the 30 identified that investigated the
specific gene expression to clinical parameters including debulking
outcomes. Seven of these used reverse-transcriptase PCR (RT–
PCR) of mRNA to determine gene expression, one used a different
method of quantification, the RiboQuant Multi-Probe RNAse
protection assay system (mRNA electrophoresis) (Komiyama et al,
2011). The data are summarised in Supplementary Table 2.
Increased gene expression of IGF1R (An et al, 2009), insulin-like
growth factor-2 promoter transcripts (Lu et al, 2006), vascular
endothelial growth factor C (VEGF-C) (Sinn et al, 2009), SRA1
(Leoutsakou et al, 2006), transforming growth factor-beta 1
(TCGFb1) (Komiyama et al, 2011), Coxsackie-adenovirus receptor
isoforms (CAR3/7 CAR4/7) (Reimer et al, 2007) and lower gene
expression of the RNAse III enzyme Drosher (Merritt et al, 2008)
have all been found to be associated with suboptimal debulking. It
is of note that the studies vary in genes investigated promoter
transcripts and definitions of optimal and suboptimal debulking.
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The use of microarray platforms has enabled a wider exploration
of the potential association between gene expression patterns. Of
the 30 identified studies, 3 publications have specifically explored
this relationship with debulking status. The first published work
(Berchuck et al, 2004) performed in 2004 used Affymetrix U133A
GeneChip microarray to explore expression patterns in association
with optimal (p1 cm residual disease) vs suboptimal debulking
surgery (41 cm residual disease). Using frozen tissue samples
from 44 patients undergoing primary surgery for stage 3 or 4
serous EOC, 120 genes were associated with debulking status with
a significance of Po0.01. Seventeen of these exhibited 42-fold
expression between the two groups. A statistical model correlation
was used to define 32 genes, which could be incorporated into a
predictive model with an accuracy of 72.7%. Genes of interest
included mitogen protein kinase (MAP) family; a metastasis
suppressor gene, retinoic acid receptor-b (RARB) and p53
inducible protein P2X6. The authors concluded that the study
supports the hypothesis that there are biological differences
between tumours that are optimally vs suboptimally debulked.
This analysis however has limitations through the absence of
adjusting for multiple comparisons by FDR and a lack of
independent data set validation. A similar study (Levine et al,
2004) has reported opposing results. Gene expression microarray
(on the same U133A platform) was performed using 70 fresh
frozen tissues from stage 3 and 4, high-grade serous ovarian
cancers. Using a supervised class comparison, they found no
differentially expressed genes between optimal (p1 cm) and
suboptimal (41 cm) debulking groups using an FDR of 10%. A
follow-on study (Bonome et al, 2008), with a larger sample size of
185 serous histology tumours, concluded that expression profiling
could not distinguish between optimally and suboptimally
debulked tumours. Additionally, only 21 probes out of 22 283
were differentially expressed between the two groups.
One additional seminal study using expression profiling (Tothill
et al, 2008) found 6 molecular subtypes following microarray gene
expression profiling on 285 serous and endometroid tumours of
the ovary, peritoneum and fallopian tube. Although not identified
by the systematic literature search, this study found that out of the
four subtypes which represented high-grade cancers there was a
significant difference of residual disease volume between the
groups. Approximately 50% of patients in the k-Means clustering
subtype group C1 were suboptimally debulked compared with
11–27% of patients in the other high-grade subtype groups.
Interestingly, this subtype group showed enhanced expression of
the ‘stromal gene cluster’ that included pathways of enrichment of
extracellular matrix production and remodelling, cell adhesion and
angiogenesis. This difference in debulking surgery may however be
attributed to the fact that a larger proportion of patients in the C1
group had primary peritoneal carcinoma, a disease that presents
with a diffuse tumour pattern which is often not possible to
remove completely at surgery.
Other translational studies
Other microarray-based technologies, such as comparative geno-
mic hybridisation that provides a genome-wide survey of copy
number changes, have also been utilised to study relationship
between surgical outcome and biological factors. In one such
study (Tan et al, 2011) investigating 50 ovarian clear cell
carcinomas used hierarchical unsupervised clustering and deter-
mined 2 distinct groups based on copy number changes, both of
which had an equal numbers of patients with residual disease
o2 cm and 42 cm (P¼ 0.687). The immunological response to
ovarian cancer has also been studied in relation to debulking
surgery (Barnett et al, 2010). Fresh-frozen EOC tumours were
obtained from 232 women at primary debulking surgery, and
tumour infiltrating T cells were determined through immuno-
histochemistry. The mean number of T-regulatory cells (CD4þ
CD25þ T cells) were observed to be higher in suboptimally
(X1 cm) debulked patients compared with those optimally
debulked (o1 cm) (n¼ 145, P¼ 0.04). Epigenetic alterations are
being increasingly investigated as potential biomarkers for
diagnosis, prognosis and treatment targets. Only one published
study has described relationship of DNA methylation with surgical
debulking outcome specifically. This study (Fiegl et al, 2008) using
MethyLight assay of fresh-frozen EOC tumours demonstrated that
HOXA11 methylation levels were found to be significantly different
between tumours that had o2 cm residual disease vs 42 cm
residual disease (n¼ 92, P¼ 0.002). Again, these studies arise from
heterogeneous tumour types with early and late stage disease and
variable histopathological grades (including borderline tumours).
Validation through TCGA data set
Odds ratios were calculated from a sample of the included studies
(Fiegl et al, 2008; An et al, 2009; Li et al, 2011) and were found to
be 0.47, 0.13 and 0.23, respectively. These looked at the
associations between having low levels (dichotomised at the
median) of IGF1R, HOXA11 or AEG1, respectively, with sub-
optimal debulking (as compared with optimal debulking). Using
an a of 0.05 and the TCGA sample size of 279, the power to detect
previously seen effects in the TCGA data was 0.69, 0.99 and 0.98,
respectively. Although it is possible that lack of validation could
occur by chance, based on these examples we believe that the
TCGA validation set was adequately powered to detect effects of
the size seen in previously published studies.
We aimed to validate the published data on candidate genes and
proteins using the TCGA data set. Data were available on 279
patients with stage 3 or 4 serous EOC who had details of residual
disease volume. In all, 274 (98.2%) patients had high-grade disease.
In all, 36 gene expression probes were found to cover the
individual gene and proteins previously identified as being
significantly associated with surgical debulking (Supplementary
Tables 1 and 2). There was no coverage of the genes SRA or BCAR1
(encodes protein P130cas). The list of 120 genes significantly
associated with debulking status found by Berchuck et al was not
validated as the gene expression probe IDs were not made
publically available. Using individual generalised linear models
adjusting for microarray batch, age and stage and adjusting for
multiple comparisons using FDR, two probes; MTDH (probe ID
‘212250_at’) and IGF1R (probe ID ‘208441_at’) were found to be
significantly differentially expressed (Po0.05, FDR o5%) asso-
ciated with optimal (p1 cm residual disease) or suboptimal
(41 cm residual disease) surgery. MTDH, which transcribes
AEG-1 protein, demonstrated increased gene expression in those
suboptimally debulked compared with those optimally debulked
with an increased log expression level of 0.24 (P¼ 0.002, FDR
3.7%, 95% confidence interval (CI) 0.088, 0.392). This correlates
with the previous data that found increased protein expression of
AEG-1 was associated with suboptimal debulking (Li et al, 2011).
IGF1R expression was found to be significantly decreased in those
with suboptimally debulked disease with a reduced log expression
level of 0.073 (P¼ 0.0004, FDR 1.4%, CI  0.112,  0.033). This
contrasts to previously reported data (An et al, 2009) that found a
significant association with increased gene expression of IGF1R
and suboptimal debulking (41 cm residual disease).
Recent emphasis has been placed on achieving total macro-
scopic surgical debulking (microscopic residual disease) with clear
survival benefits (Winter et al, 2008). Therefore, the analysis was
repeated with surgical debulking groups defined as either
microscopic (0 mm) residual disease or X1 mm macroscopic
residual disease. In this analysis, all three MTDH probes (probe ID
‘212251_at’, ‘212250_at’ and ‘212248_at’) were significantly asso-
ciated with residual disease of X1 mm (Po0.05, FDRo5%) with
their increased log expression (b¼ 0.414, P¼ 1.02E 05,
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q¼ 0.0004, CI 0.233, 0.595, b¼ 0.344, P¼ 0.0002, q¼ 0.004, CI
0.163, 0.525, and b¼ 0.39, P¼ 0.001 q¼ 0.01, CI 0.159, 0.620).
The DNA methylation data were also used in an attempt to
validate the previous published findings that differential methyla-
tion of HOXA11 was significantly associated with residual disease
(Fiegl et al, 2008). Using individualised linear models adjusting for
microarray batch, age and stage there was no significant difference
in methylation between the optimal or suboptimal groups
(P¼ 0.681) or between those with p2 cm residual disease or
42 cm residual disease (P¼ 0.559).
DISCUSSION
Significant differential expression at Po0.05 and FDR o10% was
found only in 2 out of 36 available gene expression probes between
optimal and suboptimal groups in the TCGA data set. Although it
is possible that lack of validation could occur by chance, this is
highly unlikely for most markers in TCGA where the power of the
validation analysis is expected to be 40.9. Only one of the
significant probes, MTDH (also known as AEG-1) was found to
correlate with the previous published study. Upregulation of
MTDH has been found to inhibit apoptosis and increase the
invasive ability of malignant cells (Emdad et al, 2007; Liu et al,
2010) and is involved in angiogenesis (Emdad et al, 2009). Despite
this, it is apparent that there is still no clear well-validated evidence
for a role of tumour biology on surgical success in the treatment
for EOC. We would argue however that this has been due to
limitations of study design. Previous studies have been hetero-
geneous in design without fully fulfilling REMARK (McShane et al,
2005) criteria. The REMARK report stated the importance of
transparent and complete reporting in the publication of research
on tumour markers, highlighting the need for clear descriptions of
patient and specimen characteristics, assay methods, study design
and statistical analysis.
In the majority of previous studies, early FIGO stage disease has
been included in analysis. By its very definition, of disease
confined to the ovary or pelvis (FIGO, 1987), stage 1 and 2 disease
can always or almost always be completely excised. Consequently,
a much higher proportion of optimally or total macroscopic
debulked tumours will occur in those with early stage disease
(Wimberger et al, 2007). This is not adjusted for in the majority of
analysis and thus any differences may more be by association with
stage and metastasis rather than surgical outcomes. It is now
agreed that EOC is not a single disease, but a general term applied
to a distinct set of cancers that share an anatomical location
(Vaughan et al, 2011). There are even distinct diseases within the
same histological subtype, a high-grade serous tumours being
clinically and molecularly distinct from a low-grade serous tumour
(Bowtell, 2010). Thus, the majority of previous studies have
extremely heterogeneous samples included. Interestingly, the study
with the most homogenous of tumour samples; high-grade, high-
stage serous EOC (Bonome et al, 2008) did not find any statistical
significant differences in gene expression microarray between
patients who were optimally and suboptimally debulked.
There is also discrepancy between studies when defining
surgical groups, with suboptimal debulking described as residual
disease 41 or 2 cm. Furthermore, there may be significant
measurement error with regards to tumour estimation
(Pre´fontaine et al, 1994) leading to bias in analysis. Much
emphasis is now placed in achieving total macroscopic debulking
(microscopic residual disease) with clear survival benefits (Winter
et al, 2008). We propose that this would be a more suitable
classification for molecular studies because a category of presence
or absence of macroscopic residual disease is likely to be less
susceptible to errors in measurement. This may explain the
addition of two further MTDH gene probes in TCGA analysis,
which were found to be significantly differentially expressed when
surgical groups were defined as microscopic residual disease or
X1 mm macroscopic residual disease.
It is clear that there are many clinical factors that will impact
surgical success. Debulking rates are known to differ dependent on
surgical expertise, institution and country (Nguyen et al, 1993;
Crawford et al, 2005; Skı´rnisdo´ttir and Sorbe, 2007). Personal and
institutional philosophy on what accounts as unresectable disease
also differs (Chi and Schwartz, 2008) and will undoubtedly affect
debulking rates. It has been shown that the incorporation of
extensive upper abdominal procedures such as diaphragm
peritonectomy, splenectomy and partial liver resection increased
successful cytoreductive outcomes and consequently significantly
improves survival (Chi et al, 2009). Thus, detailed descriptions on
surgical effort involved to achieve debulking outcomes should also
be considered in analysis. Surgical effort could be simply
quantified through a grid-scoring system similar to a previously
published ranking system for measurement of metastatic deposits
before surgery (Eisenkop et al, 2003; Fotopoulou et al, 2010). The
abdomen divided into anatomical segments, for example, right
upper quadrant (diaphragm, liver, adjacent peritoneal surfaces),
left upper quadrant (spleen, stomach, transverse colon and splenic
flexure), pelvis (including recto-sigmoid), etc., with a numerical
score assigned dependent on surgical resection at that site, a higher
score given for resection of major organs as compared with
excision of small nodules or plaques. Anecdotally, there are also
clinically heterogeneous tumours described at surgery. For
instance, some tumours present as widespread miliary disease
with small deposits dispersed throughout the abdomen whereas
others are more bulky with large solitary deposits at specific sites.
This pattern of disease spread is likely to affect debulking
outcomes in the majority of departments and thus should also
be recorded and included in multivariate analysis. Additionally,
patient’s performance status, age and comorbidity can also
influence surgical outcome (Wimberger et al, 2007). When all this
is considered it appears naive to attribute a molecular signature to
a surgical outcome without detailed knowledge of these important
clinical characteristics.
SUMMARY
The relationship between surgical outcome and tumour biology is
complex and remains unclear. To date, there are no specific
predictive models for surgical success that are clinically useful and
the majority of previous studies have limitations in design making
their interpretation difficult. We suggest that further effort is made
into collecting detailed clinical and surgical information in ovarian
cancer to allow for important clinical characteristics that are
known to affect surgical outcomes. This should include patient
performance status, accurate sizing and location of disease before
and after surgery and the extent of surgical effort performed.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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